רווח למניה בשנים עשר החודשים האחרונים: Jilin Zhengye Biotechnology (ZYBT)

The rolling 12-month earnings per share trend visualizes the financial trajectory, where the -0.20 mark indicates the profit level. Zhengye Biotechnology (ZYBT) develops its own vaccines, outsourcing only the logistics to external partners. Growth is driven by the modernization of Chinese farms and new swine pharmaceuticals. A strong team of virologists, motivated by scientific research grants, solidifies this success.
פילוחים אנליטיים של חברת Zhengye Biotechnology (ZYBT)

Professional managers utilize fundamental filters to assess real capital efficiency, where the trailing 12-month net income per share consolidates the final financial result of four quarters divided by the total number of securities. For Zhengye Biotechnology (ZYBT), this metric reflects the monetization of unique patents and biosanitary advantages; therefore, the trend in the trailing 12-month net income per share confirms the business resilience within the closed niche of veterinary vaccines.